| abstract |
A compound that reduces the activity or expression of a programmed death polypeptide (PD-1) for use in a method to relieve or prevent a cancer symptom in a subject, wherein said compound is an antibody against PD-1, an antibody against PD-L1, an RNAi molecule against PD-1, an RNAi molecule against PD-L1, an antisense RNA against PD-1, or an antisense RNA against PD-L1; where cancer is a lymphocytic predominance nodular Hodgkin lymphoma. |